Chenying Guo

Chenying Guo joined Flagship Pioneering in 2024 as Senior Director of Translational Sciences, accountable for translational research and biomarker strategy supporting Pioneering Medicine’s portfolio.

Chenying has experience spanning preclinical discovery and early clinical development in multiple therapeutic areas and modalities. Before joining Flagship, she was an Associate Director at Johnson and Johnson Innovative Medicine (JJIM), leading translational research for retinal diseases portfolio. Before JJIM, she served as the Director of Biomarker Research at Annexon Biosciences, accountable for translational biomarker strategy and clinical biomarker readout for a pipeline spanning autoimmune disorders, neuromuscular and neurodegenerative diseases. She previously served as a program and team lead at Novartis Institutes for Biomedical Research (NIBR), supporting multiple discovery stage programs for glaucoma, limbal stem cell deficiency, and dry eye.

Chenying has publications in areas of neurodegeneration, ophthalmology and immunology. She and her teams have supported a diverse pipeline of Ph1-Ph3 programs and contributed to the IND and CTA filing of four Ph1-Ph2 programs including small molecule and antibody drug candidates for treating neurodegenerative and immunological rare diseases.

Before joining the biotech industry, Chenying was a postdoctoral researcher at Harvard Medical School studying intrinsic mechanisms controlling CNS neuron regenerative capacity. Her work led to two patents and the founding of a startup biotech for glaucoma and retinal neuroprotection. She completed her Ph.D. at the University of California—Los Angeles, studying retina neurophysiology.